Physician profile
Harshraj Leuva
NPI 1184017618
$707.05
in general payments reported to CMS, 2019-2025
14 companies · $57.65 in 2025
The $57.65 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $146 · 2022: $256 · 2023: $20.37 · 2024: $227 · 2025: $57.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $305.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma Global Development | $227.07 | 2024 | Padcev |
| E.R. Squibb & Sons, L.L.C. | $150.53 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.65 | 2025 | |
| Incyte Corporation | $56.81 | 2022 | |
| Puma Biotechnology, INC. | $52.28 | 2022 | |
| Amgen INC. | $26.48 | 2022 | |
| Myovant Sciences INC. | $23.64 | 2022 | |
| Gilead Sciences, INC. | $21.73 | 2021 | |
| Novartis Pharmaceuticals Corporation | $20.37 | 2023 | |
| Taiho Oncology, INC. | $20.09 | 2022 | |
| Pfizer INC. | $17.52 | 2022 | |
| Array Biopharma INC | $17.08 | 2022 | |
| Seagen INC. | $15.80 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harshraj Leuva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.